John A. Bittl
A5086611754- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Peripheral Artery Disease Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Valve Diseases and Treatments
- Vascular Procedures and Complications
- Cerebrovascular and Carotid Artery Diseases
- Central Venous Catheters and Hemodialysis
- Advanced MRI Techniques and Applications
- Atrial Fibrillation Management and Outcomes
- Cardiac and Coronary Surgery Techniques
- Aortic aneurysm repair treatments
- Dialysis and Renal Disease Management
- Cardiovascular Function and Risk Factors
- Renal and Vascular Pathologies
- Pain Management and Treatment
- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Cardiac Ischemia and Reperfusion
American College of Cardiology
2011-2025
University of Massachusetts Boston
2022
Association of Chartered Certified Accountants
2011-2021
Munroe Regional Medical Center
2009-2018
National Center for Health Statistics
2015-2017
The University of Texas Southwestern Medical Center
2017
Liverpool Heart and Chest Hospital
2017
University of Liverpool
2017
Society of Thoracic Surgeons
2011-2016
Capricor Therapeutics (United States)
2016
Kristian Thygesen∗ (Denmark) Joseph S. Alpert∗ (USA) Allan Jaffe (USA) Bernard R. Chaitman (USA) Jeroen J. Bax (The Netherlands) David A. Morrow (USA) Harvey D. White∗ (New Zealand) Hans Mickley (Denmark) Filippo Crea (Italy) Frans Van de Werf (Belgium) Chiara Bucciarelli-Ducci (
Context The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but not widely tested contemporary percutaneous intervention (PCI). Objective To determine the of bivalirudin, glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications PCI, compared plus planned Gp blockade regard to protection from periprocedural ischemic hemorrhagic complications. Design, Setting,...
The incidence of coronary perforation using new percutaneous revascularization techniques may be increased compared with PTCA. Still, is uncommonly reported, and the optimal management expected outcome remain unknown. objectives study were to determine balloon angioplasty (percutaneous transluminal angioplasty, PTCA) develop strategies for its based on classification outcome.Eleven sites frequent use devices prospective coding consecutive procedures during 1990 1991 contributed a registry....
regions, sexes, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, by inviting organizations professional societies with related
Heparin is often administered during and after coronary angioplasty to prevent closure of the dilated vessel. However, ischemic or hemorrhagic complications occur in 5 10 percent treated patients. We studied whether these could be prevented when direct thrombin inhibitor bivalirudin (Hirulog) was used place heparin.We performed a double-blind, randomized trial 4098 patients undergoing for unstable postinfarction angina. Patients were assigned receive either heparin immediately before...
The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for detection, management, prevention of disease. When properly applied, expert analysis available data on benefits risks these therapies can improve quality care, optimize patient outcomes, favorably affect costs by focusing resources most effective strategies. An organized directed approach thorough review has resulted production clinical practice guidelines that assist...